News briefing: Takeda reports PhIII failure for Ninlaro in multiple myeloma; AstraZeneca plots pivot to Nasdaq
Takeda’s plans for Ninlaro have hit a road block.
The pharma giant reported Thursday that its Phase III study adding their drug to lenalidomide and dexamethasone has failed against a placebo combo using the industry standards for multiple myeloma.
The triplet failed, registering a 13.5-month increase in median progression-free survival, 35.3 months compared to 21.8 months for the sugar pill addition. That was not statistically significant. The p value was 0.073.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
